Research Article| Volume 27, ISSUE 6, P762-764, November 2013

Download started.


Vocal Fold Vibration After Photofrin-Mediated Photodynamic Therapy for Treatment of Early-Stage Laryngeal Malignancies

Published:October 10, 2013DOI:



      To analyze vocal fold vibration after photofrin-mediated photodynamic therapy (PDT) for the treatment of Tis and T1N0M0 squamous cell carcinoma (SqCCa) tumors of the larynx. It was hypothesized that key attributes of vocal fold vibration would return to baseline within 1–6 months of treatment.

      Study Design



      Laryngovideostroboscopic data were retrospectively analyzed for eight patients with Tis-T1N0M0 SqCCa tumors of the larynx treated with photofrin-mediated PDT. Baseline and posttreatment videostroboscopy images of select vibratory characteristics of the vocal folds were randomized and analyzed by a speech-language pathologist and fellowship-trained laryngologist specializing in voice disorders.


      Significant improvement in mucosal wave (P=0.003) and amplitude of vibration (P=0.004) occurred at greater than or equal to 20 weeks post-PDT compared with baseline. Comparing results within 5 weeks postprocedure to 10–19-weeks postprocedure revealed significant improvement in amplitude of vibration (P=0.013) and nonvibrating portion of the vocal fold (P=0.020). Comparing results within 5-weeks postprocedure to 20 or more weeks postprocedure revealed significant improvement in amplitude of vibration (P=0.001), mucosal wave (P=0.001), and nonvibrating portion of the effected fold (P=0.001).


      Photofrin-mediated PDT allows for preservation of function and structure of the larynx without systemic toxicity; however, it may take 4–5 months or more for key vibratory characteristics of the vocal folds to recover posttreatment.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Voice
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


      1. National Cancer Institute. Available at:

        • Schweitzer V.G.
        PHOTOFRIN-mediated photodynamic therapy for treatment of early stage oral cavity and laryngeal malignancies.
        Lasers Surg Med. 2001; 29: 305-313
        • Rigual N.R.
        • Thankappan K.
        • Cooper M.
        • et al.
        Photodynamic therapy for head and neck dysplasia and cancer.
        Arch Otolaryngol Head Neck Surg. 2009; 135: 784-788
        • Biel M.A.
        Photodynamic therapy and the treatment of neoplastic diseases of the larynx.
        Laryngoscope. 1994; 104: 399-404
        • Biel M.A.
        Photodynamic therapy treatment of early oral and laryngeal cancers.
        Photochem Photobiol. 2007; 83: 1063-1068
        • Biel M.A.
        Photodynamic therapy in head and neck cancer.
        Curr Oncol Rep. 2002; 4: 87-96
        • Biel M.A.
        Photodynamic therapy of head and neck cancers.
        Methods Mol Biol. 2010; 635: 281-293
        • Triesscheijn M.
        • Bass P.
        • Schellens J.H.M.
        • Stewart F.
        Photodynamic therapy in oncology.
        Oncologist. 2006; 11: 1034-1044
        • Copper M.P.
        • Triesscheijn M.
        • Tan I.B.
        • Ruevekamp M.C.
        • Stewart F.A.
        Photodynamic therapy in the treatment of multiple primary tumours in the head and neck, located to the oral cavity and oropharynx.
        Clin Otolaryngol. 2007; 32: 185-189
        • Grant W.E.
        • Speight P.M.
        • Hopper C.
        • Brown S.G.
        Photodynamic therapy: an effective but non-selective treatment for superficial cancers of the oral cavity.
        Int J Cancer. 1997; 71: 937-942
        • Mlynarek A.
        • Kost K.
        • Gesser R.
        Radiotherapy versus surgery for early T1-T2 glottic carcinoma.
        J Otolaryngol. 2006; 35: 413-419
        • Mendenhall W.M.
        • Werning J.W.
        • Hinerman R.W.
        • Amdur R.J.
        • Villaret D.B.
        Management of T1-T2 glottic carcinomas.
        Cancer. 2004; 100: 1786-1792
        • Peeters A.J.G.E.
        • vanGough C.D.L.
        • Goor K.M.
        • Verdonck-de Leeuw I.M.
        • Langendijk J.A.
        • Mahieu H.F.
        Health status and voice outcome after treatment for T1a glottic carcinoma.
        Eur Arch Otorhinolaryngol. 2004; 261: 534-540
        • Hocevar-Boltezar I.
        • Zargi M.
        Voice quality after radiation therapy for early glottic cancer.
        Arch Otolaryngol Head Neck Surg. 2000; 126: 1097-1100
        • Jacobson B.K.
        • Johnson A.J.
        • Grywalski C.
        • Silbergleit A.K.
        • Jacobson G.
        • Benninger M.
        • Newman C.
        The voice handicap index: development and validation.
        Am J Speech Lang Pathol. 1997; 6: 66-70
        • Cohen S.M.
        • Garrett C.G.
        • Dupont W.D.
        • Ossoff R.H.
        • Courey M.S.
        Voice-related quality of life in T1 glottic cancer: irradiation versus endoscopic excision.
        Ann Otol Rhinol Laryngol. 2006; 115: 581-586
        • Haigentz M.
        • Silver C.E.
        • Corry J.
        • Geden E.M.
        • Takes R.P.
        • Rinaldo A.
        • Ferlito A.
        Current trends in initial management of oropharyngeal cancer: the declining use of open surgery.
        Eur Arch Otorhinolaryngol. 2009; 266: 1845-1855